222 related articles for article (PubMed ID: 23222697)
1. Rat model of blood-brain barrier disruption to allow targeted neurovascular therapeutics.
Martin JA; Maris AS; Ehtesham M; Singer RJ
J Vis Exp; 2012 Nov; (69):e50019. PubMed ID: 23222697
[TBL] [Abstract][Full Text] [Related]
2. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts.
Remsen LG; Pagel MA; McCormick CI; Fiamengo SA; Sexton G; Neuwelt EA
Anesth Analg; 1999 Mar; 88(3):559-67. PubMed ID: 10072006
[TBL] [Abstract][Full Text] [Related]
3. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
4. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.
Kroll RA; Pagel MA; Muldoon LL; Roman-Goldstein S; Fiamengo SA; Neuwelt EA
Neurosurgery; 1998 Oct; 43(4):879-86; discussion 886-9. PubMed ID: 9766316
[TBL] [Abstract][Full Text] [Related]
5. A blood-brain barrier disruption model eliminating the hemodynamic effect of ketamine.
Fortin D; Adams R; Gallez A
Can J Neurol Sci; 2004 May; 31(2):248-53. PubMed ID: 15198452
[TBL] [Abstract][Full Text] [Related]
6. An advanced focused ultrasound protocol improves the blood-brain barrier permeability and doxorubicin delivery into the rat brain.
Jung B; Huh H; Lee EH; Han M; Park J
J Control Release; 2019 Dec; 315():55-64. PubMed ID: 31669208
[TBL] [Abstract][Full Text] [Related]
7. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
Fortin D; McCormick CI; Remsen LG; Nixon R; Neuwelt EA
Neurosurgery; 2000 Jul; 47(1):199-207. PubMed ID: 10917363
[TBL] [Abstract][Full Text] [Related]
8. Technique of, and complications attributable to, repeated hyperosmotic blood-brain barrier disruption in dogs.
Culver B; Inzana K; Jones J; Troy G; Kroll R; Culver B; Jortner B
Am J Vet Res; 1998 Nov; 59(11):1503-10. PubMed ID: 9829415
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound and Microbubble-Mediated Blood-Brain Barrier Disruption for Targeted Delivery of Therapeutics to the Brain.
O'Reilly MA; Hynynen K
Methods Mol Biol; 2018; 1831():111-119. PubMed ID: 30051428
[TBL] [Abstract][Full Text] [Related]
10. Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption.
Foley CP; Rubin DG; Santillan A; Sondhi D; Dyke JP; Crystal RG; Gobin YP; Ballon DJ
J Control Release; 2014 Dec; 196():71-78. PubMed ID: 25270115
[TBL] [Abstract][Full Text] [Related]
11. Multiple regression analysis of a comprehensive transcriptomic data assembly elucidates mechanically- and biochemically-driven responses to focused ultrasound blood-brain barrier disruption.
Mathew AS; Gorick CM; Price RJ
Theranostics; 2021; 11(20):9847-9858. PubMed ID: 34815790
[No Abstract] [Full Text] [Related]
12. Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses.
Burks SR; Kersch CN; Witko JA; Pagel MA; Sundby M; Muldoon LL; Neuwelt EA; Frank JA
Proc Natl Acad Sci U S A; 2021 May; 118(18):. PubMed ID: 33906946
[TBL] [Abstract][Full Text] [Related]
13. Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointervention.
Chen L; Liu J; Chu C; Han Z; Yadav N; Xu J; Bai R; Staedtke V; Pearl M; Walczak P; van Zijl P; Janowski M; Liu G
Theranostics; 2021; 11(13):6240-6250. PubMed ID: 33995656
[No Abstract] [Full Text] [Related]
14. Localized Down-regulation of P-glycoprotein by Focused Ultrasound and Microbubbles induced Blood-Brain Barrier Disruption in Rat Brain.
Cho H; Lee HY; Han M; Choi JR; Ahn S; Lee T; Chang Y; Park J
Sci Rep; 2016 Aug; 6():31201. PubMed ID: 27510760
[TBL] [Abstract][Full Text] [Related]
15. A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy.
Lamsam L; Johnson E; Connolly ID; Wintermark M; Hayden Gephart M
Neurosurg Focus; 2018 Feb; 44(2):E10. PubMed ID: 29385922
[TBL] [Abstract][Full Text] [Related]
16. Blood-Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade.
Virtanen PS; Ortiz KJ; Patel A; Blocher WA; Richardson AM
Curr Oncol Rep; 2024 Mar; 26(3):236-249. PubMed ID: 38329660
[TBL] [Abstract][Full Text] [Related]
17. Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.
Doolittle ND; Muldoon LL; Culp AY; Neuwelt EA
Adv Pharmacol; 2014; 71():203-43. PubMed ID: 25307218
[TBL] [Abstract][Full Text] [Related]
18. Comparison and evaluation of osmotic blood-brain barrier disruption following intracarotid mannitol and methylglucamine iothalamate.
Sage MR; Wilcox J; Evill CA; Benness GT
Invest Radiol; 1982; 17(3):276-81. PubMed ID: 6811497
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies.
Cosolo WC; Martinello P; Louis WJ; Christophidis N
Am J Physiol; 1989 Feb; 256(2 Pt 2):R443-7. PubMed ID: 2492773
[TBL] [Abstract][Full Text] [Related]
20. Dynamic perfusion assessment by contrast-enhanced ultrasound in blood-brain barrier disruption.
Lin WH; Fan CH; Ting CY; Liu HL; Yeh CK
Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():1152-5. PubMed ID: 24109897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
